Bank of America kicks off coverage of Alvotech with a buy rating, citing biosimilar launch momentum

Bank of America Securities initiated coverage of Alvotech S.A. with a buy rating and a $7 price objective, a note sent into markets as the biosimilar launch cycle narrative gathers attention again.

According to the report published by Yahoo Finance, BofA’s target comes against a share price of $4.43 as of Monday, implying a sizable gap between the analyst’s view and the market’s level at the time of the initiation.

The investment case described in the write-up is linked to timing around the Food and Drug Administration inspection process. BofA pointed to the FDA’s closure of its inspection of Alvotech, framing the development as a potential step toward enabling the company’s biosimilar launch plans.

For context, biosimilars are follow-on versions of already-approved biologic drugs, designed to be highly similar in terms of safety and effectiveness, with regulatory pathways that still require rigorous manufacturing and quality controls. Launch cycle timing, including regulatory and inspection milestones, can matter because it can affect when products move from approvals and readiness efforts into commercial distribution.

BofA’s coverage initiation also adds a fresh bank-research perspective to a sector where patient confidence, manufacturing execution, and regulatory clearance often drive expectations. In biosimilars, even when a product’s clinical or regulatory groundwork is set, the ability to produce consistently to agency standards can remain a gating factor for commercialization schedules.

Still, the available market coverage does not provide additional details in the published excerpt on which specific Alvotech products are most relevant to the “launch cycle” referenced, nor does it lay out what, if any, incremental financial modeling assumptions BofA tied to the FDA closure beyond the general momentum theme.

It also remains unclear from the excerpt whether Alvotech has provided additional operational updates alongside the FDA development, such as any changes to manufacturing timelines, supply commitments, or commercialization preparations. As with many initiation notes, the full assumptions and sensitivities may be contained in the original research document rather than the brief market write-up.

What to watch next is whether Alvotech provides more detail about how the FDA inspection closure translates into concrete near-term milestones, such as production readiness, distribution start dates, or guidance adjustments. For investors tracking biosimilars, follow-through on timing is typically what turns inspection-related progress into commercial visibility.